American BioDental acquires Omnigene Diagnostics:
This article was originally published in Clinica
American BioDental has purchased Omnigene Diagnostics. The acquisition is part of a major restructuring at American BioDental and will be the first of many acquisitions in the dentistry and related fields, says the company. American BioDental, the parent company of Minimatic Implant Technology, obtained $1 million capital through two investment companies based in the Bahamas and Abu Dabi to part-finance the deal. Omnigene develops DNA probe-based tests for periodontal disease diagnosis. MIT develops and markets precision components for dental implants.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.